Dr. Aman et al. reply - 21/06/13

Doi : 10.1016/j.jaac.2010.01.017

Michael G. Aman, Ph.D. ^a,^⁎ , L. Eugene Arnold, M.Ed., M.D. ^a, Luc Lecavalier, Ph.D. ^a, Jill A. Hollway, M.A. ^a, James A. Mulick, Ph.D. ^a, Christopher J. McDougle, M.D. ^b, Naomi B. Swiezy, Ph.D. ^b, Kimberly A. Stigler, M.D. ^b, Benjamin L. Handen, Ph.D. ^c, Cynthia Johnson, Ph.D. ^c, Benedetto Vitiello, M.D. ^d, Karen Bearss, Ph.D. ^e, James Dziura, Ph.D. ^e, Lawrence Scahill, M.S.N., Ph.D. ^e
^a The Ohio State University, Columbus, OH
^b Indiana University, Indianapolis, IN
^c University of Pittsburgh, Pittsburgh, PA
^d National Institute of Mental Health, Rockville, MD
^e Yale University, New Haven, CT

Correspondence to: Dr. Michael G. Aman, Ohio State University, The Nisonger Center for Developmental Disabilities, 1581 Dodd Drive, Ohio State University, Columbus, OH 43210-1296

Le texte complet de cet article est disponible en PDF.

	All statements expressed in this column are those of the authors and do not reflect the opinions of the Journal or the American Academy of Child and Adolescent Psychiatry. See the Instructions for Authors for information about the preparation and submission of Letters to the Editor.
	This work was funded by the National Institute of Mental Health by the following RUPP grants: Ohio State University, U10MH66768; Indiana University, U10MH66766; and Yale University, U10MH66764. Johnson & Johnson Pharmaceutical Research & Development provided active risperidone for the study.
	The National Institutes of Health participation is reflected above in individual authors' contributions. The views expressed in this article are those of the authors and do not necessarily reflect the official position of the National Institute of Mental Health, the National Institutes of Health, or any other part of the U.S. Department of Health and Human Services.
	Disclosure: Dr. Aman received recent contract support from Johnson & Johnson and Bristol-Myers Squibb. Dr. Arnold has served as a consultant to Abbott, Neuropharm, Novartis, Arganon, Shire, Targacept, and Noven; and received research support from CureMark, Neurophram, Shire, and Eli Lilly; and has served as a speaker for Shire and Novartis. Dr. Scahill has receieved recent contract support from Boehringer–Ingelheim, Bristol-Myers Squibb, Shire, Neuropharm, Supernus, and Janssen. Dr. McDougle has served as a consultant to, has received research support from, and has served on the speakers' bureau of Bristol-Myers Squibb Co. Drs. Stigler, Vitiello, Swiezy, Johnson, Dziura, Lecavalier, Handen, Mulick, Bearss, and Hollway report no biomedical financial interests or potential conflicts of interest.